Business Context and Reporting Period
This Form 8-K filing by Aptevo Therapeutics Inc. (APVO) is dated June 30, 2025. The report addresses a compliance issue regarding the company's continued listing on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses the following capital raising activities during the quarter ended June 30, 2025:
- Total Gross Proceeds Raised: Approximately $15.9 million in equity capital.
- Stockholders' Equity: The company believes it now holds at least $2.5 million, meeting the minimum requirement for Nasdaq Listing Rule 5550(b)(1).
Specific equity transactions included:
- April 4, 2025: Registered direct offering and private placement of warrants; gross proceeds of approximately $2.1 million.
- April 22, 2025: Registered direct offering of common stock; gross proceeds of approximately $2.0 million.
- June 20, 2025: Registered direct offering of common stock (or pre-funded warrants) and warrants; gross proceeds of approximately $8.0 million.
- April 28, 2025 – June 30, 2025: At The Market Offering Agreement sales; aggregate gross proceeds of approximately $3.8 million.
Material Changes
The primary material change is the restoration of compliance with Nasdaq listing standards. Previously, the company received a notice of non-compliance for the quarter ended March 31, 2025, due to stockholders' equity falling below the $2.5 million threshold. The recent equity offerings have reversed this deficit.
Outlook, Risks, and Management Commentary
Management states that the company believes it is now in compliance with Nasdaq Listing Rule 5550(b)(1). The filing notes that the company is awaiting formal confirmation from the Nasdaq Listing Qualifications Staff. An update will be provided to the market upon receipt of a formal compliance determination. No specific operational guidance or risk factors beyond the listing status were detailed in this specific report.
Investor Verification Checklist
- Confirm receipt of formal compliance determination from Nasdaq.
- Verify the exact post-offering stockholders' equity balance in the next quarterly report (10-Q).
- Review the dilution impact of the $15.9 million in equity raised on existing shareholders.
- Monitor future cash burn rates to ensure sustained compliance with listing requirements.